CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00361231
NCT00361231Phase 2Completed
CompareCT.gov

Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer

Massachusetts General Hospital·interventional·Posted Aug 8, 2006·Updated Feb 7, 2017

In Brief

A Phase 2 clinical trial evaluating Bevacizumab, Gemcitabine, and 1 other intervention for Biliary Tract Cancer and Gallbladder Adenocarcinoma. Completed, enrolled 35 participants across 2 sites.

Detailed Summary

The purposes of this study are to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good and bad) this combination has on patients with cancer of bile duct or gallbladder. Bevacizumab has been shown to slow or stop cell growth in tumors by decreasing the blood supply to the tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer, Gallbladder Adenocarcinoma
CountriesUnited States
CollaboratorsGenentech, Inc., Sanofi, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2006
Enrollment StartMay 1, 2006
Primary CompletionMar 1, 2009
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.9 years ago

Interventions

Bevacizumabdrug

Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.

Gemcitabinedrug

Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.

Oxaliplatindrug

Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.